Willkommen, schön sind Sie da!
Logo Ex Libris

BRAF Targets in Melanoma

  • Kartonierter Einband
  • 212 Seiten
(0) Erste Bewertung abgeben
Alle Bewertungen ansehen
This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will... Weiterlesen
CHF 179.00
Print on Demand - Auslieferung erfolgt in der Regel innert 4 bis 6 Wochen.
Bestellung & Lieferung in eine Filiale möglich


This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that this drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.

Examines BRAF-directed targets in melanoma including molecular biology/signal transduction, molecular diagnostics, immunology, and next-generation analytics

Highlights and summarizes the unique biological mechanisms of how BRAF-inhibitors work and why they ultimately fail

Explores combinations of molecular targeted therapy and how molecular targeted therapy may interact with immune-based therapy

Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.


1. Melanoma: Historical Context

Suraj Venna, Sekwon Jang, Michael Atkins

2. Melanoma Pathogenesis

Jennifer A. Lo, David E. Fisher

3. Molecular Diagnostics and Tumor Mutational Analysis

Melissa A. Wilson and Katherine L. Nathanson

4. Clinical Utility of BRAF-targeted therapy in Melanoma

Jeffrey A. Sosman and Douglas B. Johnson

5. The Ethics of Randomized Trials in Oncology

Pallavi Kumar, Ryan J. Sullivan

6. Parallel and Serial Blockade Strategies in BRAF-Mutant Melanoma

Michael A. Davies

7. Targeting the cell cycle and p53 in combination with BRAF-directed therapy

Dale Han, Keiran SM Smalley

8. Combination BRAF-directed therapy and immunotherapy

Zachary A. Cooper, Zain Ahmed, Jennifer A. Wargo

9. Moving Forward: Making BRAF-Targeted Therapy Better

Keith T Flaherty


Titel: BRAF Targets in Melanoma
Untertitel: Biological Mechanisms, Resistance, and Drug Discovery
EAN: 9781493953486
ISBN: 1493953486
Format: Kartonierter Einband
Herausgeber: Springer New York
Genre: Medizin
Anzahl Seiten: 212
Gewicht: 330g
Größe: H235mm x B155mm x T11mm
Jahr: 2016
Auflage: Softcover reprint of the original 1st ed. 2015

Weitere Produkte aus der Reihe "Cancer Drug Discovery and Development"